Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Promyelocytic, Acute 10Neuroblastoma 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 2Thrombocytopenia 2Pathologic Complete Response 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Melanoma 2Colorectal Neoplasms 2Wilms Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Mouth Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Lymphoma 1Leiomyosarcoma 1Kidney Neoplasms 1HER2 Negative Breast Cancer 1Glioma 1

Interventions

pembrolizumab 3apatinib 3Magnetic Resonance Spectroscopy 3lenvatinib 2Specimen Handling 2Nivolumab 2Imatinib Mesylate 2Epirubicin 2Cisplatin 2Carboplatin 2Axitinib 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2regorafenib 1gallium 68 PSMA-11 1enfortumab vedotin 1cabozantinib 1avelumab 1anlotinib 1amivantamab 1Tretinoin 1Sunitinib 1Radiation 1Pemetrexed 1Nelfinavir 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Lutetium-177 1Lutetium 1Ipilimumab 1Glutamate Carboxypeptidase II 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Adenoid Cystic × Tretinoin × Clear all
NCT03999684 2023-01-23

A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

Dana-Farber Cancer Institute

Phase 2 Completed
18 enrolled 8 charts

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡